Unraveling the genetics of transformed splenic marginal zone lymphoma

被引:18
|
作者
Grau, Marta [1 ]
Lopez, Cristina [1 ,2 ,3 ]
Navarro, Alba [1 ,2 ,3 ]
Frigola, Gerard [4 ]
Nadeu, Ferran [1 ,3 ]
Clot, Guillem [1 ,2 ,3 ]
Bastidas-Mora, Gabriela [5 ]
Alcoceba, Miguel [3 ,6 ]
Baptista, Maria Joao [7 ]
Blanes, Margarita [8 ]
Colomer, Dolors [1 ,3 ,4 ]
Costa, Dolors [1 ,3 ,4 ]
Domingo-Domenech, Eva [9 ]
Enjuanes, Anna [3 ,10 ]
Escoda, Lourdes [11 ]
Forcada, Pilar [12 ]
Gine, Eva [1 ,3 ]
Lopez-Guerra, Monica [1 ,3 ]
Ramon, Olga [13 ]
Rivas-Delgado, Alfredo [1 ,5 ]
Folch, Laura Vicente [14 ]
Wotherspoon, Andrew [15 ]
Climent, Fina [16 ]
Campo, Elias [1 ,3 ,4 ]
Lopez-Guillermo, Armando [2 ,3 ,5 ]
Matutes, Estella [5 ]
Bea, Silvia [1 ,2 ,3 ,4 ,17 ]
机构
[1] Inst Invest Biomed August Pi i Sunyer, Fundacio Clin Recerca Biomed, Mol Pathol Lymphoid Neoplasms, Barcelona, Spain
[2] Univ Barcelona, Barcelona, Spain
[3] Ctr Invest Biomed Red Canc, Madrid, Spain
[4] Hosp Clin Barcelona, Dept Pathol, Hematopathol Sect, Barcelona, Spain
[5] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
[6] Univ Hosp Salamanca, Canc Res Inst Salamanca, Dept Hematol, Salamanca, Spain
[7] Hosp Germans Trias i Pujol, Josep Carreras Leukaemia Res Inst, Inst Catala Oncol, Dept Hematol, Barcelona, Spain
[8] Hosp Gen Univ Elda, Dept Hematol, Alicante, Spain
[9] Hosp Duran i Reynals, Inst Catala Oncol, Inst Invest Biomed Bellvitge, Dept Hematol, Barcelona, Spain
[10] Inst Invest Biomed August Pi i Sunyer, Fundacio Clin Recerca Biomed, Unitat Genomica, Barcelona, Spain
[11] Hosp Joan 23, Inst Catala Oncol, Dept Hematol, Tarragona, Spain
[12] Hosp Univ Mutua Terrassa, Dept Hematol, Terrassa, Spain
[13] Hosp Gen Igualada, Dept Hematol, Igualada, Spain
[14] Consorci Sanit Terrassa, Dept Hematol, Terrassa, Spain
[15] Royal Marsden NHS Fdn Trust, Dept Histopathol, London, England
[16] Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge, Dept Pathol, Hosp Llobregat, Barcelona, Spain
[17] Fundacio Clin Recerca Biomed, Mol Pathol Lymphoid Neoplasms, Inst Invest Biomed August Pii Sunyer, Rossello 153, Barcelona 08036, Spain
基金
欧盟地平线“2020”;
关键词
B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; MUTATIONS; GENOME; NOTCH2; CLASSIFICATION; PATHOGENESIS; SUBGROUPS; DELETIONS; GENES;
D O I
10.1182/bloodadvances.2022009415
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients with SMZL that eventually underwent large B-cell lymphoma transformation. Tumor material was obtained either only at diagnosis (9 patients), at diagnosis and transformation (18 patients), and only at transformation (14 patients). Samples were categorized in 2 groups: (1) at diagnosis (SMZL, n = 27 samples), and (2) at transformation (SMZL-T, n = 32 samples). Using copy number arrays and a next-generation sequencing custom panel, we identified that the main genomic alterations in SMZL-T involved TNFAIP3, KMT2D, TP53, ARID1A, KLF2, 1q gains, and losses of 9p21.3 (CDKN2A/B) and 7q31-q32. Compared with SMZL, SMZL-T had higher genomic complexity, and higher incidence of TNFAIP3 and TP53 alterations, 9p21.3 (CDKN2A/B) losses, and 6p gains. SMZL and SMZL-T clones arose by divergent evolution from a common altered precursor cell that acquired different genetic alterations in virtually all evaluable cases (92%, 12 of 13 cases). Using whole-genome sequencing of diagnostic and transformation samples in 1 patient, we observed that the SMZL-T sample carried more genomic aberrations than the diagnostic sample, identified a translocation t(14;19)(q32;q13) present in both samples, and detected a focal B2M deletion due to chromothripsis acquired at transformation. Survival analysis showed that KLF2 mutations, complex karyotype, and International Prognostic Index score at transformation were predictive of a shorter survival from transformation (P = .001; P = .042; and P = .007; respectively). In summary, SMZL-T are characterized by higher genomic complexity than SMZL, and characteristic genomic alterations that could represent key players in the transformation event.
引用
收藏
页码:3695 / 3709
页数:15
相关论文
共 50 条
  • [31] Hyperviscosity syndrome in splenic marginal zone lymphoma
    Daniel, Raeye
    Chan, Randall Y.
    BLOOD, 2018, 132 (15) : 1627 - 1627
  • [32] Primary Splenic and Nodal Marginal Zone Lymphoma
    Diebold, Jacques
    Le Tourneau, Agnes
    Comperat, Eva
    Molina, Thierry
    Jose e Audouin
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2005, 45 (01) : 1 - 14
  • [33] Splenic marginal zone lymphoma with increased prolymphocytes
    Cai, Jennifer
    Qing, Xin
    BLOOD, 2021, 137 (22) : 3150 - 3150
  • [34] A new taxonomy for splenic marginal zone lymphoma
    Deaglio, Silvia
    Vaisitti, Tiziana
    BLOOD, 2022, 139 (05) : 644 - 645
  • [35] Rituximab monotherapy for splenic marginal zone lymphoma
    Bennett, Michael
    Sharma, Kumud
    Yegena, Shaiy
    Gavish, Israel
    Dave, Harish P.
    Schechter, Geraldine P.
    HAEMATOLOGICA, 2005, 90 (06) : 856 - 858
  • [36] Splenic lymphoma with circulating villous lymphocytes splenic marginal-zone lymphoma
    Catovsky, D
    Matutes, E
    SEMINARS IN HEMATOLOGY, 1999, 36 (02) : 148 - 154
  • [37] Transformation of a splenic marginal zone lymphoma into classic Hodgkin lymphoma
    Menter, Thomas
    Dirnhofer, Stefan
    Tzankov, Alexandar
    JOURNAL OF CLINICAL PATHOLOGY, 2019, 72 (05) : 391 - 392
  • [38] Defining the borders of splenic marginal zone lymphoma (SMZL)
    Dufresne, S. D.
    Felgar, R. E.
    Cook, J. R.
    Sargent, R. L.
    Gollin, S. M.
    Swerdlow, S. H.
    MODERN PATHOLOGY, 2008, 21 : 252A - 252A
  • [39] TREATMENT OF SPLENIC MARGINAL ZONE NON HODGKIN LYMPHOMA
    Manaka, A.
    Kyriazi, V.
    Vagia, M.
    Liapis, K.
    Panitsas, F.
    Michelis, F.
    Kakkas, I.
    Gigantes, S.
    Delibasi, S.
    Pagoni, M.
    Baltathakis, I.
    Apostolidis, J.
    Karakasis, D.
    Bakiri, M.
    Karmiris, T.
    Harhalakis, N.
    Nikiforakis, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 557 - 558
  • [40] Clinical and biological diversity of splenic marginal zone lymphoma
    Matutes, Estella
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (09) : 1185 - 1189